Lionheart Health Recognized as Top Implantable Stimulator Developer by MedTech Outlook

Lionheart Health, Inc., a pioneer in biotech and medical device innovation, has been honored with the title of Top Implantable Stimulator Developer of the Year by MedTech Outlook. This accolade highlights the company's groundbreaking contributions to the field of healthspan, longevity, and organ regeneration through its patented KlothoImplant™ and MicroImplant™ stimulator technologies. These devices are designed to deliver precise bioelectric signaling sequences that control regenerative protein expression, facilitating stem cell homing, muscle building, blood vessel growth, and inflammation reduction.

The collaboration between Lionheart Health and Leonhardt Ventures LLC has led to the development of a bioelectric stimulation platform with applications ranging from organ regeneration to hearing restoration. The technology has been tested across a variety of applications, including the regeneration of the heart, bladder, kidneys, and other vital organs, demonstrating its versatility and potential to revolutionize medical treatments.

MedTech Outlook's recognition of Lionheart Health underscores the importance of the company's work in advancing medical technology. With over 500 issued and pending patent claims, multiple FDA 510(k) market clearances, and ongoing applications, Lionheart Health is at the forefront of developing implantable stimulators that have passed rigorous testing, including for total heart and kidney regeneration.

Brian Lasater, CTO of Lionheart Health, expressed gratitude for the recognition, emphasizing the team's dedication to innovation. The company's achievements, including being named a Top 40 semifinalist in the XPRIZE Healthspan competition, reflect its commitment to extending healthspan and longevity through bioelectric signaling. For more information, visit https://www.LionheartLongevity.com, https://www.lionhearthealthstim.com, and https://www.LeonhardtVentures.com.